drugset
drugset / Trial / NCT02475317

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

NCT02475317 ↗

Phase 1 Completed 84 enrolled Mirum Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this study is to assess the relative potency of multiple oral doses of LUM001 and SHP626 administered for 7 days as assessed by fecal bile acid excretion in overweight and obese adult subjects. This study is designed to address the relative potency question for the first time in the same.

Timeline

Start
2015-06-01
Primary completion
2015-12-01
Completion
2015-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Maralixibat Small molecule 10 mg Oral
Subject Maralixibat Small molecule 20 mg Oral
Subject Maralixibat Small molecule 50 mg Oral
Subject Maralixibat Small molecule 100 mg Oral
Subject Volixibat Small molecule 10 mg Oral
Subject Volixibat Small molecule 20 mg Oral

Indications

No indication recorded.